Anecortave

Anecortave is a synthetic derivative of cortisol, a steroid hormone produced by the adrenal glands. It was developed by Alcon Laboratories for the treatment of age-related macular degeneration (AMD) and angiogenesis (the formation of new blood vessels). However, it is not currently approved for use in any country.

Mechanism of Action

Anecortave inhibits angiogenesis by suppressing the production of vascular endothelial growth factor (VEGF), a protein that promotes the growth of new blood vessels. This makes it potentially useful in treating conditions like AMD, where abnormal blood vessel growth in the retina can lead to vision loss.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of anecortave. In a Phase II trial, anecortave was found to slow the progression of AMD in some patients. However, a subsequent Phase III trial did not meet its primary endpoint, and development of the drug was discontinued.

Side Effects

The most common side effects of anecortave include eye pain, cataract formation, and increased intraocular pressure. These side effects are generally mild and resolve on their own after treatment is discontinued.

See Also

• Cortisol
• Age-related macular degeneration
• Angiogenesis
• Vascular endothelial growth factor

Anecortave Resources
Latest articles Most recent articles Ongoing trials	Wikipedia